Dr Ruben Mesa, an international MPN expert provides a summary of the highlights for MPN patients from the December 2022 American Society of Hematology (ASH) annual meeting.

CALR monoclonal antibody discovered!
Of particular note is the incredibly exciting news of the discovery of a CALR monoclonal antibody which has proven very successful in the laboratory. The CALR mutation is responsible for roughly 30% of ET and MF cases.
Patient clinical trials are expected to commence in the upcoming year. A measure of the importance of this breakthrough is that the research was featured in a plenary session at the conference.
Here is a link to a video from Ann Mullaly, MPN specialist and scientist from the US,  explaining in more detail how the CALR mutation is being targeted. (courtesy of MPN Hub).

Secondly, the video below from Ruben Mesa provides an overview of this and other promising developments from ASH.
Anne Brazeau, the founder and CEO of MPN Education and Advocacy International has kindly made available this video to the MPNAA.